<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01453595</url>
  </required_header>
  <id_info>
    <org_study_id>11-080</org_study_id>
    <nct_id>NCT01453595</nct_id>
  </id_info>
  <brief_title>BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)</brief_title>
  <official_title>A Phase 1b/2 Study of BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study tests a new medication for treatment of kidney cancer, called BEZ235. This
      medication works by blocking several mechanisms that the cancer needs to grow and survive. By
      blocking these mechanisms, the medication can thus suppress further growth of the cancer,
      possibly kill cancer cells. Older kidney cancer medications (such as temsirolimus [Torisel®]
      or everolimus [Afinitor®]) typically only block one mechanism in cancer cells, so the
      investigators think that BEZ235 may work even better against kidney cancer.

      The purpose of the first part of this study is to test the safety of giving BEZ235 at
      different doses. The investigators are trying to find a safe dose of BEZ235 and want to find
      out what effects, good and/or bad, it has on the patient and the cancer.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Given the number of toxicities seen and the difficulty with patient retention in the dose
    escalation portion, the sponsor decided to close the trial.
  </why_stopped>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>1 year</time_frame>
    <description>In patients with advanced clear cell RCC, progressing after prior first-line or second-line mTOR therapy. The determination of antitumor efficacy will be based on objective tumor assessments made according to the RECIST1.1.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Renal Cancer</condition>
  <arm_group>
    <arm_group_label>BEZ235</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a single-institution, open label, single-arm Phase 1b/2 trial of BEZ235 in patients with advanced RCC. The study will be conducted in two phases:
Phase 1b: dose-escalation will be performed to determine the maximally tolerated dose (MTD) of twice daily BEZ235 to use in Phase 2 (RP2 dose).
Phase 2: subjects with clear cell who have experienced disease progression on prior first or second-line mTOR targeted therapy will be treated on the MTD of twice daily BEZ235.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BEZ235</intervention_name>
    <description>BEZ235 will be taken orally twice daily starting on Day 1, Cycle 1, self-administration will continue twice daily on a continuous schedule with cycle length defined as 28 days. Increasing dosing levels of BEZ235 will be studied sequentially (beginning with Dose Level 1, BEZ235 400mg by mouth twice daily) as per the treatment noted below.
Cohort-1a BEZ235 300 mg by mouth twice daily Cohort 1 BEZ235 400 mg by mouth twice daily Cohort 2 BEZ235 600 mg by mouth twice daily Cohort 3 BEZ235 800 mg by mouth twice daily</description>
    <arm_group_label>BEZ235</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced renal cell carcinoma. Advanced disease is defined as unresectable, locally
             recurrent disease or metastatic disease. This must by confirmed by MSKCC pathology
             review with the following requirements:

          -  Phase 1b: Any histologic subtype of RCC.

          -  Phase 2: clear cell type RCC or predominant clear cell component.

        Patients will be screened for prior systemic therapies:

          -  Phase 1b: Any prior therapy.

          -  Phase 2: Progression of disease on at least one prior treatment with an mTOR inhibitor
             (such as everolimus, temsirolimus, ridaforolimus). Other prior systemic therapies
             including VEGF directed therapy (e.g. sunitinib, sorafenib, bevacizumab) and
             immunotherapy (e.g. IL-2, interferon-α) are also permitted. Evidence of
             unidimensionally measurable disease per RECIST 1.1 (Eisenhauer, Therasse et al. 2009).

          -  Resolution of all acute toxic effects of prior systemic treatments, radiotherapy or
             surgical procedures to NCI CTCAE Version 4.0 grade ≤1.

          -  Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2, which
             is not declining during the last 2 weeks.

          -  18 years of age or older.

        Adequate organ function as defined by the following criteria:

          -  Absolute neutrophil count (ANC) ≥1,000/μL

          -  Platelets ≥100,000/μL

          -  Hemoglobin ≥9.0 g/dL

          -  Serum calcium ≤12.0 mg/dL

          -  Serum creatinine ≤1.5 x upper limit of normal (ULN); if this is exceeded, estimated
             creatinine clearance must be ≥ 30 ml/min

          -  Total serum bilirubin ≤ 1.5 x ULN (in patients with known Gilbert Syndrome, a total
             bilirubin of ≤ 3 x ULN, with direct bilirubin ≤ 1.5 x ULN)

          -  Serum aspartate transaminase (AST) and serum alanine transaminase (ALT)

             ≤3 x ULN (≤5 x ULN in the setting of hepatic metastases)

          -  INR ≤ 2. (Anticoagulation with warfarin is contraindicated)

          -  Fasting plasma glucose (FPG) ≤ 140mg/dL

          -  HgbA1c ≤ 8%

          -  Fasting serum cholesterol ≤300 mg/dL, fasting triglycerides ≤ 2.5 x ULN. NOTE: In case
             one or both of these thresholds are exceeded, the patient can only be included after
             initiation of appropriate lipid lowering medication. Signed and dated informed consent
             document indicating that the subject (or legally acceptable representative) has been
             informed of all pertinent aspects of the trial prior to undergoing study screening
             procedures.

          -  Subject's willingness and ability to comply with scheduled visits, treatment plans,
             laboratory tests, and other study procedures.

        Exclusion Criteria:

          -  Patients who have received prior treatment with a P13K inhibitor (Phase 2 portion
             only).

          -  Patients within 28 days post major surgery (e.g., intra-thoracic, intra-abdominal or
             intra-pelvic) or significant traumatic injury.

          -  Patients who had radiation therapy within 28 days prior to start of study treatment
             (palliative radiotherapy to bone lesions allowed if completed 2 weeks prior to study
             treatment start).

          -  Patients who have received chemotherapy, immunotherapy or other investigational agents
             ≤ 2 weeks prior to study treatment start.

        Patients currently receiving medications known to be inducers or moderate / strong
        inhibitors of CYP3A4 (see table 9.2 for a list) Patients must discontinue such medications
        ≥ 7 days prior to initiation of study treatment.

          -  Patients currently receiving medications with a significant risk to induce Torsades de
             Pointes

          -  Patients who are currently receiving treatment with warfarin sodium (Coumadin®). If
             treatment is discontinued or switched to an alternate anticoagulant prior to
             enrollment, INR within ≤48h prior to study initiation has to return to ≤ 2 x ULN.

          -  Patients receiving chronic treatment with systemic corticosteroids or other
             immunosuppressive agents (inhaled or topical steroids are allowed)

          -  Patients with evidence or history of central nervous system (CNS) metastases or spinal
             cord compression, unless prior treatment with surgery or radiotherapy AND no
             progression of CNS disease within 6 months prior to enrollment. Patients must not be
             receiving chronic corticosteroid therapy for CNS metastases.

          -  Patients who have a history of severe medical conditions or other conditions that
             could affect their participation in the study such as:

          -  symptomatic intrinsic lung disease requiring oxygen supplementation at baseline

          -  uncontrolled hypertension (i.e., SBP&gt;180 mmHg or DBP &gt;100mmHg)

          -  any active (acute or chronic) or uncontrolled infection/disorders that impair the
             ability to evaluate the patient or for the patient to complete the study

          -  liver disease such as cirrhosis or decompensated liver disease.

          -  Impairment of gastrointestinal function that may impair absorption of BEZ235 (e.g.
             ulcerative diseases, uncontrolled nausea/vomiting; diarrhea ≥ grade 2; malabsorption
             syndromes after prior small-bowel resection)

          -  Immunocompromised patients and/or history of HIV seropositivity

        Patients with prior or current cardiac problems including:

          -  History of unstable angina pectoris (at any time), symptomatic congestive heart
             failure (NYHA III, IV) (at any time), serious uncontrolled cardiac arrhythmia (at any
             time), myocardial infarction or cerebrovascular accidents ≤ 6 months prior to first
             study treatment or history of left ventricular dysfunction

          -  reduced left ventricular ejection fraction (LVEF) of &lt;50% on screening with
             echocardiogram or multiple gates acquisition (MUGA) scan

          -  severe valvulopathies with documented compromise in cardiac function

          -  Any of the following on screening ECG:

          -  QTc interval &gt; 480 msec (or family history of congenital QTc prolongation)

          -  Right bundle branch block + left anterior hemiblock (bifascicular block)

          -  Complete left bundle branch block

          -  Any conduction abnormality requiring pacemaker

          -  Symptomatic sinus bradycardia

          -  Any ventricular arrhythmia except for benign premature ventricular contractions

          -  Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with
             medication

          -  Symptomatic pericarditis

          -  Documented cardiomyopathy of any cause

          -  Female patients who are pregnant or breast feeding; pregnancy is defined as the state
             of a female after conception and until the termination of gestation, confirmed by a
             positive serum βhCG laboratory test (&gt; 5 mIU/mL).

          -  Patients unwilling or unable to comply with adequate double barrier contraception
             throughout the trial and for 12 weeks after the last dose of study drug (by both male
             and female patients). This includes the following considerations:

          -  Hormonal contraceptives may be affected by cytochrome P450 interactions, and are
             therefore considered neither indicated nor effective.

          -  Adequate barrier methods of contraception include: diaphragm, condom (by the partner),
             intrauterine device (copper), sponge or spermicide.

          -  Women are considered post-menopausal and not of child bearing potential if they have
             had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile
             (e.g., age appropriate, history of vasomotor symptoms) or six months of spontaneous
             amenorrhea with serum FSH levels &gt; 40 mIU/mL [for US only: and estradiol &lt; 20 pg/mL]
             or have had surgical bilateral oophorectomy (with or without hysterectomy) at least
             six weeks ago. In the case of oophorectomy alone, only when the reproductive status of
             the woman has been confirmed by follow up hormone level assessment is she considered
             not of child bearing potential

          -  Patients who have a history of another primary malignancy and are off treatment for ≤
             3 years, with the exception of non-melanoma skin cancer and carcinoma in situ of the
             uterine cervix.

          -  Patients who have received attenuated live vaccines within one week of study entry.
             Examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral
             polio, BCG, yellow fever, varicella and TY21a typhoid vaccines.

          -  Known intolerance to the study drug (or any of the excipients), and/or known
             hypersensitivity to PI3K inhibitor (eg. GDC-0980), and/or known hypersensitivity to
             rapamycins (eg. Sirolimus, everolimus, temsirolimus) or any of the excipients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Molina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan-Kettering Cancer Center</description>
  </link>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2011</study_first_submitted>
  <study_first_submitted_qc>October 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2011</study_first_posted>
  <results_first_submitted>December 14, 2015</results_first_submitted>
  <results_first_submitted_qc>February 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 29, 2016</results_first_posted>
  <last_update_submitted>February 1, 2016</last_update_submitted>
  <last_update_submitted_qc>February 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney</keyword>
  <keyword>renal cell carcinoma</keyword>
  <keyword>BEZ235</keyword>
  <keyword>11-080</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dactolisib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: BEZ235 400mg</title>
          <description>Cohort 1: BEZ235 400mg by mouth twice daily</description>
        </group>
        <group group_id="P2">
          <title>Cohort -1: BEZ235 200mg</title>
          <description>Cohort -1: BEZ235 200mg by mouth twice daily</description>
        </group>
        <group group_id="P3">
          <title>Cohort -1a: BEZ235 300mg</title>
          <description>Cohort -1a: BEZ235 300mg by mouth twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Dose Limiting Toxicity (DLT)</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1: BEZ235 400mg</title>
          <description>Cohort 1: BEZ235 400mg by mouth twice daily</description>
        </group>
        <group group_id="B2">
          <title>Cohort -1: BEZ235 200mg</title>
          <description>Cohort -1: BEZ235 200mg by mouth twice daily</description>
        </group>
        <group group_id="B3">
          <title>Cohort -1a: BEZ235 300mg</title>
          <description>Cohort -1a: BEZ235 300mg by mouth twice daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate (ORR)</title>
        <description>In patients with advanced clear cell RCC, progressing after prior first-line or second-line mTOR therapy. The determination of antitumor efficacy will be based on objective tumor assessments made according to the RECIST1.1.</description>
        <time_frame>1 year</time_frame>
        <population>ORR was only assessed for participants who completed the study, which were only 5 patients on Cohort -1</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort -1: BEZ235 200mg</title>
            <description>Cohort -1: BEZ235 200mg by mouth twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR)</title>
          <description>In patients with advanced clear cell RCC, progressing after prior first-line or second-line mTOR therapy. The determination of antitumor efficacy will be based on objective tumor assessments made according to the RECIST1.1.</description>
          <population>ORR was only assessed for participants who completed the study, which were only 5 patients on Cohort -1</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Progression of Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1: BEZ235 400mg</title>
          <description>Cohort 1: BEZ235 400mg by mouth twice daily</description>
        </group>
        <group group_id="E2">
          <title>Cohort -1: BEZ235 200mg</title>
          <description>Cohort -1: BEZ235 200mg by mouth twice daily</description>
        </group>
        <group group_id="E3">
          <title>Cohort -1a: BEZ235 300mg</title>
          <description>Cohort -1a: BEZ235 300mg by mouth twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Given the number of toxicities seen and the difficulty with patient retention in the dose escalation portion, the sponsor decided to close the trial.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Martin Voss</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>646-422-4631</phone>
      <email>vossm@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

